ProCE Banner Series

ProCE Pharmacy Education Series: Tackling the Patient Burden of Systemic Mastocytosis: Pharmacy-Focused Strategies to Improve Patient Outcomes

Systemic mastocytosis (SM) is a heterogeneous condition characterized by dysregulation of mast cells and by manifestations, including anaphylaxis, that have a profound impact on patients’ lives. Treatment has been limited to symptom management and trigger avoidance, but new therapies are emerging that address underlying drivers of SM, such as KIT inhibitors, and pharmacists need to understand the data on these medications so they can facilitate their safe and effective use to improve outcomes for patients with SM.

  ACPE-P
Who Should Attend

This activity is intended for pharmacists, including retail, specialty, managed care, community, outpatient, and ambulatory care pharmacists, who care for patients with systemic mastocytosis.

All Events

ProCE Pharmacy Education Series: Tackling the Patient Burden of Systemic Mastocytosis: Pharmacy-Focused Strategies to Improve Patient Outcomes

Past Events

March

24

2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics

Systemic mastocytosis

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this educational activity is to improve the knowledge and competence of pharmacists in the management of patients with systemic mastocytosis to improve patient outcomes.

Target Audience
This activity is intended for pharmacists, including retail, specialty, managed care, community, outpatient, and ambulatory care pharmacists, who care for patients with systemic mastocytosis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the key drivers of SM that lead to its heterogeneous presentation

  • Apply safety and efficacy data for new SM therapies to optimize patient outcomes

  • Implement strategies to address barriers to optimal patient care in patients with SM

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-25-005-L01-P has been assigned to this application-based activity (initial release date 3/24/2025). This activity is approved for 1.0 contact hour (0.10 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC

Supported by an educational grant from Blueprint Medicines Corporation.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191